Management of entecavir-resistant chronic hepatitis B with adefovir-based combination therapies

Figure 1 Changes of hepatitis B virus DNA levels during 48 wk. A: The overall mean changes of hepatitis B virus (HBV) DNA levels from baseline; B: The mean reduction of serum HBV DNA levels in adefovir plus entecavir (ADV/ETV) combination group and in the adefovir plus lamivudine (ADV/LMV) combination group.

Figure 2 Virologic responses according to type of treatments up to 36 mo. A: Overall cumulative virologic response rates at 6, 12, 24, and 36 mo; B: Cumulative virologic response rates in the adefovir plus entecavir (ADV/ETV) combination group and in the adefovir plus lamivudine (ADV/LMV) combination group (P = 0.048).

Figure 3 Virologic responses according to the presence of favorable factors. A: Cumulative virologic response rates in patients with low baseline serum hepatitis B virus (HBV) DNA levels and in patients with high baseline serum HBV DNA levels (P < 0.001); B: Cumulative virologic response rates in patients with and without initial virologic response-3 (IVR-3) (P < 0.001).

Figure 4 Virologic responses according to the number of predictive factors. Cumulative virologic response rates in patients with 2, 1, and 0 favorable factors are presented (P < 0.001).

Figure 5 Development of virological breakthrough. A: Overall cumulative virological breakthrough (VBT) rates; B: Cumulative incidence of VBT at 36 mo according to the number of favorable predictors.